Eagle IP was honored to co-host the AIPLA Women in IP Global Networking Event in collaboration with the Hong Kong Science and Technology Parks Corporation (HKSTP).

This annual event, organized by the American Intellectual Property Law Association (AIPLA), took place simultaneously in over 40 cities worldwide. As the official Hong Kong host, Eagle IP welcomed a vibrant community of female leaders, innovators, entrepreneurs, and IP practitioners to the Science Park for an evening of shared experiences and professional growth.

We would like to thank HKSTP for their partnership and all the attendees who contributed to such an inspiring evening. At Eagle IP, we are proud to support the advancement of women in the field and look forward to continuing these vital conversations.

Our Past Events

Recommended Insights

NMPA's Releases Draft Measures for Data Protection (Data Exclusivity)

4 September 2025
In March 2025, China's National Medical Products Administration (NMPA) released yet another set of draft implementation measures on data protection.1 Key highlights of these new measures include the following: A Bit of History China's journey toward a comprehensive pharmaceutical data protection framework has been ongoing for over two decades, a roller coaster ride from its […]

Is it Sufficient to Claim an Antibody only by Describing its Antigen?

12 November 2018
Things may be brewing with respect to antibody inventions. Just how much description is sufficient? After losing in the Federal Circuit, Amgen has decided to ask the US Supreme Court to weigh in on a standard that could vastly influence the pharmaceutical and biotech industry. The story relates to Repatha™, an LDL-lowering drug from Amgen […]

When Standards Evolve: How China Judges Inventiveness in Next-Gen Tech Patents

30 September 2025
Starting in 2023, Datang Mobile, one of the key players in China’s telecom standardization efforts, initiated infringement proceedings against Samsung in China, Germany, and the US. Samsung responded by filing multiple invalidation petitions in several jurisdictions, including China, the United States, and Europe. The case discussed below is one of above-mentioned invalidation cases in China, […]

Beijing Supreme People’s Court Upholds Novo Nordisk Semaglutide Patent in China based on Post-Filing Data

23 January 2026
On December 31, 2025, The Supreme People's Court upheld the Beijing IP Court's decision, meaning that the semaglutide patent remains valid and will expire on March 20, 2026. Novo Nordisk announced this positive news via a press release on the day the case was decided. The Chinese Ministry of Commerce has also confirmed this decision […]
Top crossarrow-right